abstract |
The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications. |